In a Phase II trial of non-diabetic stage IIIB/IV patients with EGFR-mutated lung adenocarcinoma, the addition of metformin to EGFR tyrosine kinase resulted in improved PFS and OS (138). This evidence concerns the gene EGFR and lung adenocarcinoma.